We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-2.6%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$610B
AUM Growth
-$181B
Cap. Flow
-$168B
Cap. Flow %
-27.5%
Top 10 Hldgs %
30.63%
Holding
3,114
New
154
Increased
1,364
Reduced
1,248
Closed
171

Top Buys

Rank Stock Value
1
XOM icon
ExxonMobil
XOM
+$1.76B
2
LLY icon
Eli Lilly
LLY
+$1.4B
3
BAC icon
Bank of America
BAC
+$1.3B
4
TSLA icon
Tesla
TSLA
+$1.19B
5
WFC icon
Wells Fargo
WFC
+$784M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$6.47B
2
AMZN icon
Amazon
AMZN
+$3.71B
3
YUM icon
Yum! Brands
YUM
+$2.84B
4
CRM icon
Salesforce
CRM
+$2.77B
5
FTV icon
Fortive
FTV
+$2.41B

Sector Composition

Rank Sector Weight
1 Technology 26.06%
2 Healthcare 18.72%
3 Consumer Discretionary 14.62%
4 Financials 10.36%
5 Communication Services 9.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATEC icon
2701
Alphatec Holdings
ATEC
$1.51B
$108K ﹤0.01%
12,291
-18,637
-60% -$147K
PBYI icon
2702
Puma Biotechnology
PBYI
$450M
$108K ﹤0.01%
45,400
QTTB icon
2703
Q32 Bio
QTTB
$458M
$107K ﹤0.01%
3,667
YEXT icon
2704
Yext
YEXT
$613M
$106K ﹤0.01%
23,604
+7,493
+47% +$34.8K
ALTO icon
2705
Alto Ingredients
ALTO
$326M
$105K ﹤0.01%
28,656
+10,962
+62% +$46.1K
CRIS icon
2706
Curis
CRIS
$3.91M
$104K ﹤0.01%
369
+53
+17% +$21.4K
ORGO icon
2707
Organogenesis Holdings
ORGO
$226M
$104K ﹤0.01%
31,873
+5,052
+19% +$22.8K
IVAC
2708
DELISTED
Intevac Inc
IVAC
$104K ﹤0.01%
22,200
MMAT
2709
DELISTED
Meta Materials Inc. Common Stock
MMAT
$104K ﹤0.01%
1,596
+785
+97% +$68.7K
MRNS
2710
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$104K ﹤0.01%
15,600
BRMK
2711
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$104K ﹤0.01%
20,282
+7,824
+63% +$52.4K
BORR
2712
Borr Drilling
BORR
$1.25B
$103K ﹤0.01%
30,728
+17,905
+140% +$66.5K
CLVS
2713
DELISTED
Clovis Oncology, Inc.
CLVS
$103K ﹤0.01%
85,900
-37,550
-30% -$58.5K
INSG icon
2714
Inseego
INSG
$77.7M
$102K ﹤0.01%
4,927
+655
+15% +$15.8K
LCTX icon
2715
Lineage Cell Therapeutics
LCTX
$268M
$101K ﹤0.01%
89,100
+16,700
+23% +$24.5K
GOEV
2716
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$101K ﹤0.01%
116
+29
+33% +$42.3K
ARC
2717
DELISTED
ARC Document Solutions, Inc.
ARC
$101K ﹤0.01%
44,302
-19,200
-30% -$53.4K
SAFE
2718
Safehold
SAFE
$1.1B
$100K ﹤0.01%
+2,212
New +$154K
ENZ
2719
DELISTED
Enzo Biochem, Inc.
ENZ
$100K ﹤0.01%
44,800
LMACA
2720
DELISTED
Liberty Media Acquisition Corporation Series A Common Stock
LMACA
$100K ﹤0.01%
10,040
CHMI
2721
Cherry Hill Mortgage Investment Corp
CHMI
$108M
$99K ﹤0.01%
19,976
CNTY icon
2722
Century Casinos
CNTY
$35.2M
$99K ﹤0.01%
+15,089
New +$116K
OPTT icon
2723
Ocean Power Technologies
OPTT
$55.4M
$99K ﹤0.01%
119,800
DRRX
2724
DELISTED
DURECT Corp
DRRX
$98K ﹤0.01%
16,757
-371
-2% -$2.26K
EHTH icon
2725
eHealth
EHTH
$38.8M
$98K ﹤0.01%
24,904
+4,569
+22% +$31.9K

Similar funds

T. Rowe Price Associates's Q3 2022 Portfolio in Review

As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.

By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.

  • T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
  • T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
  • T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
  • T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
  • T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
  • T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
  • T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.